Investigational Drug Service, The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina

Investigational Drug Service, The University of North Carolina at Chapel Hill is a clinical research site located in Chapel Hill, North Carolina, United States 27514.

Crixeo Health Trust Score: 41/100 (POOR). This profile has not yet been claimed by the site owner.

Investigational Drug Service, The University of North Carolina at Chapel Hill has participated in 1 clinical trials.

Therapeutic areas: Nonalcoholic Steatohepatitis.

Sponsors: Tobira Therapeutics, Inc..

Sponsor Feasibility Report

Trust Score: 41/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Investigational Drug Service, The University of North Carolina at Chapel Hill?

Investigational Drug Service, The University of North Carolina at Chapel Hill has a Crixeo Trust Score of 41/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Investigational Drug Service, The University of North Carolina at Chapel Hill conducted?

Investigational Drug Service, The University of North Carolina at Chapel Hill has 1 clinical trials on record. Their work covers Nonalcoholic Steatohepatitis.

Is Investigational Drug Service, The University of North Carolina at Chapel Hill accredited by Crixeo Health?

Investigational Drug Service, The University of North Carolina at Chapel Hill has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Investigational Drug Service, The University of North Carolina at Chapel Hill?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.